Guidance for full-year 2026 net product sales for Jelmyto are expected to be in the range of $97 million to $101 million. This implies a year-over-year growth rate of approximately 3% to 7% over the $94 million of Jelmyto sales reported in 2025.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma announces refinanced term loan agreement with Pharmakon
- URGN Upcoming Earnings Report: What to Expect?
- UroGen Pharma announces post-hoc analyses from Phase 3 trial of Zusduri
- UroGen’s Phase 1 UGN-301 Bladder Cancer Trial Completion: What Investors Should Watch Next
- UroGen Pharma says permanent J Code for ZUSDURI now in effect